Agilent Technologies Inc., an American analytical instrumentation manufacturing company, announced it has entered into a definitive agreement to acquire Resolution Bioscience Inc., a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions.
Agilent has agreed to pay $550 million in cash at closing, under the agreement, and up to an additional $145 million depending on reaching future performance milestones.
Agilent expands capabilities in NGS-based cancer diagnostics
The purchase complements and expands Agilent’s capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market.
Resolution Bioscience’s non-invasive liquid biopsy assay platform supports both the biopharma services market and the clinical oncology diagnostic testing market and is enabled by its Clinical Laboratory Improvement Amendments (CLIA)-certified lab. The platform has been designed for both a centralized CLIA test service and a distributable kit format.
In addition, the Resolution Bioscience homologous recombination deficiency (HRD) assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration. The HRD assay is performed on a standard blood sample and detects actionable mutations in genes for identifying cancer. Back in 2020, Resolution Bioscience announced a commercial partnership with LabCorp to enable broad access to the Resolution ctDx Lung™ test that detects actionable mutations in genes associated with non-small cell lung cancer.
Mike McMullen, Agilent president and CEO commented:
“We are extremely pleased to add Resolution Bioscience’s outstanding team and powerful technology to Agilent’s growing business in precision oncology solutions. By adding Resolution Bioscience’s liquid biopsy-based diagnostic technologies to our portfolio, we are strengthening Agilent’s offering to our biopharma customers and boosting the growth of our diagnostics and genomics business. This also accelerates our strategy to broaden access to precision oncology testing for patients worldwide through distributed NGS-based diagnostic kits. We look forward to Resolution Bioscience joining with us to expand our work in the fight against cancer.”
Mark Li, Resolution Bioscience president and CEO said:
“Agilent’s broad expertise, global regulatory and commercial infrastructure, extensive partnerships with biopharma companies, and decades-long leadership in precision medicine will enhance and accelerate our groundbreaking work. We are excited to further expand the use of NGS in precision oncology for clinical diagnostics as part of the Agilent team.”
Headquartered in based in Kirkland, Washington, Resolution Bioscience had revenues of approximately $35 million in the calendar year of 2020 and is expected to generate $50 million to $55 million in 2021. The purchase is expected to be slightly dilutive to Agilent’s non-GAAP earnings per share in fiscal 2021 and 2022, and improving in the following years.
The transaction is expected to be finalized in April, subject to regulatory approvals and customary closing conditions.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted solutions to customers’ most challenging questions. Agilent has generated revenue of $5.34 billion in the fiscal year 2020 and employs approximately 16,400 people worldwide.
Information about Agilent is available at www.agilent.com.
About Resolution Bioscience
Resolution Bioscience is dedicated to developing a highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients around the globe. The company has developed and patented core technology for circulating cell-free DNA NGS analysis. The company is based in Kirkland, Washington.